Cargando…

Disabled-2 (DAB2): A Key Regulator of Anti- and Pro-Tumorigenic Pathways

Disabled-2 (DAB2), a key adaptor protein in clathrin mediated endocytosis, is implicated in the regulation of key signalling pathways involved in homeostasis, cell positioning and epithelial to mesenchymal transition (EMT). It was initially identified as a tumour suppressor implicated in the initiat...

Descripción completa

Detalles Bibliográficos
Autores principales: Price, Zoe K., Lokman, Noor A., Yoshihara, Masato, Kajiyama, Hiroaki, Oehler, Martin K., Ricciardelli, Carmela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9821069/
https://www.ncbi.nlm.nih.gov/pubmed/36614139
http://dx.doi.org/10.3390/ijms24010696
_version_ 1784865609963536384
author Price, Zoe K.
Lokman, Noor A.
Yoshihara, Masato
Kajiyama, Hiroaki
Oehler, Martin K.
Ricciardelli, Carmela
author_facet Price, Zoe K.
Lokman, Noor A.
Yoshihara, Masato
Kajiyama, Hiroaki
Oehler, Martin K.
Ricciardelli, Carmela
author_sort Price, Zoe K.
collection PubMed
description Disabled-2 (DAB2), a key adaptor protein in clathrin mediated endocytosis, is implicated in the regulation of key signalling pathways involved in homeostasis, cell positioning and epithelial to mesenchymal transition (EMT). It was initially identified as a tumour suppressor implicated in the initiation of ovarian cancer, but was subsequently linked to many other cancer types. DAB2 contains key functional domains which allow it to negatively regulate key signalling pathways including the mitogen activated protein kinase (MAPK), wingless/integrated (Wnt) and transforming growth factor beta (TGFβ) pathways. Loss of DAB2 is primarily associated with activation of these pathways and tumour progression, however this review also explores studies which demonstrate the complex nature of DAB2 function with pro-tumorigenic effects. A recent strong interest in microRNAs (miRNA) in cancer has identified DAB2 as a common target. This has reignited an interest in DAB2 research in cancer. Transcriptomics of tumour associated macrophages (TAMs) has also identified a pro-metastatic role of DAB2 in the tumour microenvironment. This review will cover the broad depth literature on the tumour suppressor role of DAB2, highlighting its complex relationships with different pathways. Furthermore, it will explore recent findings which suggest DAB2 has a more complex role in cancer than initially thought.
format Online
Article
Text
id pubmed-9821069
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98210692023-01-07 Disabled-2 (DAB2): A Key Regulator of Anti- and Pro-Tumorigenic Pathways Price, Zoe K. Lokman, Noor A. Yoshihara, Masato Kajiyama, Hiroaki Oehler, Martin K. Ricciardelli, Carmela Int J Mol Sci Review Disabled-2 (DAB2), a key adaptor protein in clathrin mediated endocytosis, is implicated in the regulation of key signalling pathways involved in homeostasis, cell positioning and epithelial to mesenchymal transition (EMT). It was initially identified as a tumour suppressor implicated in the initiation of ovarian cancer, but was subsequently linked to many other cancer types. DAB2 contains key functional domains which allow it to negatively regulate key signalling pathways including the mitogen activated protein kinase (MAPK), wingless/integrated (Wnt) and transforming growth factor beta (TGFβ) pathways. Loss of DAB2 is primarily associated with activation of these pathways and tumour progression, however this review also explores studies which demonstrate the complex nature of DAB2 function with pro-tumorigenic effects. A recent strong interest in microRNAs (miRNA) in cancer has identified DAB2 as a common target. This has reignited an interest in DAB2 research in cancer. Transcriptomics of tumour associated macrophages (TAMs) has also identified a pro-metastatic role of DAB2 in the tumour microenvironment. This review will cover the broad depth literature on the tumour suppressor role of DAB2, highlighting its complex relationships with different pathways. Furthermore, it will explore recent findings which suggest DAB2 has a more complex role in cancer than initially thought. MDPI 2022-12-31 /pmc/articles/PMC9821069/ /pubmed/36614139 http://dx.doi.org/10.3390/ijms24010696 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Price, Zoe K.
Lokman, Noor A.
Yoshihara, Masato
Kajiyama, Hiroaki
Oehler, Martin K.
Ricciardelli, Carmela
Disabled-2 (DAB2): A Key Regulator of Anti- and Pro-Tumorigenic Pathways
title Disabled-2 (DAB2): A Key Regulator of Anti- and Pro-Tumorigenic Pathways
title_full Disabled-2 (DAB2): A Key Regulator of Anti- and Pro-Tumorigenic Pathways
title_fullStr Disabled-2 (DAB2): A Key Regulator of Anti- and Pro-Tumorigenic Pathways
title_full_unstemmed Disabled-2 (DAB2): A Key Regulator of Anti- and Pro-Tumorigenic Pathways
title_short Disabled-2 (DAB2): A Key Regulator of Anti- and Pro-Tumorigenic Pathways
title_sort disabled-2 (dab2): a key regulator of anti- and pro-tumorigenic pathways
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9821069/
https://www.ncbi.nlm.nih.gov/pubmed/36614139
http://dx.doi.org/10.3390/ijms24010696
work_keys_str_mv AT pricezoek disabled2dab2akeyregulatorofantiandprotumorigenicpathways
AT lokmannoora disabled2dab2akeyregulatorofantiandprotumorigenicpathways
AT yoshiharamasato disabled2dab2akeyregulatorofantiandprotumorigenicpathways
AT kajiyamahiroaki disabled2dab2akeyregulatorofantiandprotumorigenicpathways
AT oehlermartink disabled2dab2akeyregulatorofantiandprotumorigenicpathways
AT ricciardellicarmela disabled2dab2akeyregulatorofantiandprotumorigenicpathways